Kenvue

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kenvue (KVUE) reports strong Q2 earnings, eyes China growth

Kenvue's Q2 performance showcased robust net sales, organic growth, and strategic investments in key segments. The company's focus on consumer trust, supply chain enhancements, and capital allocation strategy underpin its resilience. Challenges include managing inflationary pressures and sustaining growth post-COVID, but opportunities in China and ongoing investments position Kenvue for future success.

Kenvue (KVUE) reports solid Q3 performance amidst segment challenges

Kenvue (KVUE) delivered a solid Q3 performance, showcasing strength in key segments despite challenges in others.
The company's strategic initiatives, focus on innovation, and outlook for growth opportunities position it well for future success.
Efforts to address challenges in specific segments and capitalize on opportunities demonstrate a proactive approach to sustaining growth and profitability.
Overall positive outlook on third-quarter results reflects the company's strong model, portfolio, and cash flow generation capabilities.

Kenvue reports mixed 2023 performance, focuses on growth strategies

Kenvue's 2023 performance saw organic growth but faced challenges in specific segments, leading to adjustments for 2024. The company aims to drive growth through operational efficiencies, increased brand investments, and a focus on consumer engagement. Challenges in U.S. in-store execution prompted a recovery plan and leadership changes.

Kenvue surpasses Q1 expectations, eyes China growth amid challenges

Kenvue's Q1 performance exceeded expectations, driven by key segments and brands.
Strategic focus on cost optimization, operational efficiency, and brand impact.
Challenges include stabilizing declining segments and managing hyperinflation impact.
Opportunities lie in growing China business, operational reinvention, and new leadership.

Kenvue reports solid Q2 performance and optimistic outlook for 2024

Kenvue's Q2 performance reflects steady growth and improved profitability, driven by strategic initiatives and strong brand performance. While cost management and increased marketing spend pose challenges, the company's focus on brand investment and long-term value creation offers promising opportunities for future growth and shareholder returns.

Kenvue reports Q3 growth, tackles Skin Health challenges, eyes savings

Kenvue's Q3 performance showed organic growth and strong financial metrics.
While facing challenges in the Skin Health segment, the company is focusing on recovery.
Investments in marketing and efficiency improvements highlight growth opportunities.
Executives addressed key questions on guidance, inventory levels, and growth strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kenvue, Inc. is a consumer health company. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment focuses on oral care, baby care, women's health and wound care. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.

The heavy selling pressure might have exhausted for Kenvue (KVUE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -7.52% in 4 Weeks, Here's Why You Should You Buy the Dip in Kenvue (KVUE)

Kenvue (NYSE: KVUE ) stock is a hot topic among traders on Thursday following news that it will be added to the S&P 500 . Investors will note that Kenvue is joining the S&P 500, as well as the S&P 100, as Johnson & Johnson (NYSE: JNJ ) is splitting off a minimum of 80.1% of KVUE stock that it owns.

KVUE Stock Alert: Kenvue to Join the S&P 500

Johnson & Johnson

Kenvue is set to make its debut in the S&P 500 index, a move confirmed by S&P Dow Jones Indices following the impending completion of Johnson and Johnson's exchange offer for Kenvue stock. The inclusion comes after Kenvue's nearly $47 billion initial public offering by Johnson and Johnson in May.

J&J spinoff Kenvue set to join S&P 500 index

NEW YORK, Aug. 9, 2023 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE) will be added to the S&P 500 effective prior to the open on a date to be announced conditioned upon the successful completion of a voluntary exchange offer being conducted by S&P 500 & S&P 100 constituent Johnson & Johnson (NYSE: JNJ). Johnson & Johnson announced its intention to split off at least 80.1% of Kenvue shares it owns through a voluntary exchange offer that expires Friday, August 18. Kenvue will replace an S&P 500 company to be named in a separate press release closer to the S&P 500 addition effective date.

Kenvue Set to Join S&P 500

The Johnson & Johnson spinoff is the consumer health company that makes Listerine and Tylenol.

Kenvue Will be Added to S&P 500 After J&J Exchange Offer

Kenvue Inc., maker of Tylenol, Benadryl and other household names in health-care products, is joining the S&P 500, index provider S&P Dow Jones Indices said late Wednesday.

Kenvue, the J&J spinoff, will join the S&P 500 index

Johnson & Johnson ( JNJ , Financial) has recently announced its intention to split off Kenvue Inc. ( KVUE , Financial) shares through an exchange offer. This move marks the next step in the separation from the parent company.

Johnson & Johnson Plans Exchange Offer for Kenvue

Hershey

Kimberly-Clark

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

Top 3 Defensive Stocks That Could Lead To Your Biggest Gains In August - Kimberly-Clark (NYSE:KMB), Hershey (NYSE:HSY)

Johnson & Johnson is splitting off its consumer healthcare business to shareholders. They can exchange all, some, or none of their shares for Kenvue stock.

Dividend Investors in This Unique Stock-Split Stock Have a Decision to Make

Johnson & Johnson offers its shareholders the choice to exchange its shares for Kenvue's, the consumer health company it spun off just two months ago.

Johnson & Johnson Offers Exchange for Shares of Spinoff Kenvue

J&J said it received a waiver that dismisses the share lockup period associated with Kenvue's initial public offering in May.

Johnson & Johnson to reduce its Kenvue stake by at least 80% through exchange offer

Johnson & Johnson (NYSE:JNJ) (J&J) has launched a share exchange offer for its former consumer health business Kenvue which completed its initial public offering in May. Shareholders of J&J can opt to exchange some or all of their shares for Kenvue stock at a 7% discount, subject to certain conditions, the company announced on Monday.

Johnson & Johnson launches share exchange offering for Kenvue

Johnson & Johnson said on Monday it had launched an exchange offer for its investors to exchange J&J's shares with those of its consumer health unit Kenvue.

J&J begins share exchange offer for consumer health spin-off Kenvue

Johnson & Johnson JNJ, +1.07% said Monday it is planning to spin off at least 80.1% of its shares of Kenvue Inc. KVUE, -2.04% through an exchange offer. The consumer goods and healthcare giant announced its intention to launch an exchange offer for the separation of Kenvue, its consumer health business which went public in May, when it reported earnings last week.

Johnson & Johnson to spin off at least 80.1% of Kenvue shares in an exchange offer

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) announced intent to file a Form S-4 Registration Statement today with the Securities and Exchange Commission.

Kenvue To File Form S-4 Registration Statement in Connection with Johnson & Johnson Exchange Offer Announcement

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced its intention to split-off at least 80.1% of the shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) through an exchange offer. Kenvue, formerly Johnson & Johnson's Consumer Health business, completed its initial public offering (“IPO”) in May 2023. Through the planned exchange offer, Johnson & Johnson shareholders can exchange all, some or none of their shares of Johnson & Johnson common stock for sha.

Johnson & Johnson Launches Exchange Offer for Separation of Kenvue Inc.

Thibaut Mongon's remarks follow Kenvue's second-quarter earnings beat, which was fueled by resilient demand for brands like Band-Aid, Tylenol and Aveeno.

Kenvue CEO says consumers are spending on brand-name health products even as they pull back in other areas

J&J owns nearly 90% of Kenvue shares and plans to reduce its stake in the company through an exchange offer that could launch "as early as the coming days."

Johnson & Johnson investors can soon swap their shares for Kenvue stock — here's what you need to know

One of the more interesting moves in today's market comes from recent spinoff Kenvue (NYSE: KVUE ). Currently, shares of KVUE stock are down around 3% in today's session, as the company reported earnings that beat Wall Street estimates by a rather wide margin.

Is Johnson & Johnson Giving Up on Kenvue (KVUE) Stock?

Kenvue Inc has reported a strong set of maiden results following its spin-out from Johnson & Johnson (NYSE:JNJ) earlier this year.  The consumer health company, whose brands include Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena and Tylenol, reported a 5.4% increase in net sales for the three months to June 30, 2023.

Kenvue debuts from Johnson and Johnson with strong 2Q results

Kenvue Inc. (NYSE:KVUE ) Q2 2023 Earnings Conference Call July 20, 2023 7:30 AM ET Company Participants Tina Romani - Head, Investor Relations Thibaut Mongon - Chief Executive Officer Paul Ruh - Chief Financial Officer Conference Call Participants Anna Lizzul - Bank of America Filippo Falorni - Citi Andrea Teixeira - JPMorgan Peter Grom - UBS Jason English - Goldman Sachs Steve Powers - Deutsche Bank Navann Ty - BNP Paribas Jeremy Fialko - HSBC Operator Greetings and welcome to the Kenvue Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Kenvue Inc. (KVUE) Q2 2023 Earnings Call Transcript

J&J still owns a 90% stake in Kenvue, meaning it can generally control the direction of the consumer health spinoff's business for the time being.

Kenvue earnings top estimates in J&J spinoff's first quarterly report since IPO

Tylenol, Benadryl and Listerine brands parent Kenvue Inc. KVUE, +0.77% reported Thursday second-quarter profit and revenue that beat expectations, provided an upbeat full-year outlook and initiated a dividend. The household consumer brands company's stock was will inactive in the premarket.

Tylenol, Benadryl parent Kenvue tops earnings expectations, amid strength in pain care, cold and flu product demand

Kenvue on Thursday posted a rise in quarterly sales thanks to strong demand for its self-care and skincare brands such as Tylenol and Neutrogena.

Kenvue quarterly sales rise on strong demand for self-care products

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), today announces Board of Directors declare a dividend payable in Q3 of 2023 of $0.20 per share on the common stock.

News for Kenvue Stock (KVUE)